GLIMOT-M2 TAB

GLIMOT-M2 Tablets

The image shows Glimot-M2, labeled “Glimepiride & Metformin Hydrochloride (Prolonged Released) Tablets IP.” The manufacturer-associated listing confirms the composition as Glimepiride 2 mg + Metformin Hydrochloride 500 mg (extended release) per tablet. (Accott Healthcare India Inc.)

IngredientAmount per tabletFunctionGlimepiride2 mgSulfonylurea antidiabetic; stimulates insulin releaseMetformin Hydrochloride (ER)500 mgBiguanide antidiabetic; decreases hepatic glucose production and improves insulin sensitivityExcipientsq.s.Tablet formation, stability and prolonged-release properties

1. Glimepiride — 2 mg

• Class: Sulfonylurea antidiabetic.

• Stimulates the pancreatic β-cells to release insulin.

• Its effect is therefore dependent on functioning pancreatic β-cells.

• The main important adverse effect is hypoglycaemia, particularly if meals are skipped, the dose is excessive, or it is combined with other glucose-lowering medicines. (Accott Healthcare India Inc.)

2. Metformin Hydrochloride — 500 mg ER

• Class: Biguanide.

• The ER/prolonged-release form is designed to release metformin more gradually.

• Primarily reduces glucose production by the liver and improves insulin sensitivity, thereby lowering blood glucose.

• Gastrointestinal effects such as nausea, diarrhoea and abdominal discomfort are common, especially when starting treatment. (Accott Healthcare India Inc.)

Why the combination is used

The two medicines lower blood glucose by complementary mechanisms:

Glimepiride → increases insulin secretion
Metformin → decreases hepatic glucose production + improves insulin sensitivity

Therefore, Glimot-M2 is intended for Type 2 diabetes mellitus when combination therapy is appropriate. It is not intended for Type 1 diabetes or diabetic ketoacidosis. (Accott Healthcare India Inc.)

Important point about the prolonged-release tablet

Because this is a prolonged/extended-release formulation, it should generally be swallowed whole rather than crushed or chewed, unless the product's prescribing information specifically permits otherwise. The manufacturer-associated information also recommends taking it after food/as directed by the physician. (Accott Healthcare India Inc.)

Excipients

The exact manufacturer-specific excipient list and quantities are not visible on the front of the box, so I would not invent them. The confirmed active composition is:

Glimot-M2 = Glimepiride 2 mg + Metformin Hydrochloride 500 mg ER per tablet. (Accott Healthcare India Inc.)

Main caution: Because glimepiride can cause low blood sugar, symptoms such as sweating, shakiness, hunger, dizziness, confusion or weakness should be taken seriously. Metformin also requires particular caution in significant kidney impairment.